Moreover, organoid biobank covered different mutation subtypes, and its application in drug screening could yield key associations between mutation types and drug sensitivities, such as CRC organoids harbored TP53 mutation was insensitive to MDM2 inhibitors (van de Wetering et al., 2015), the missense mutations of ARID1A in pancreatic cancer are associated with increased sensitivity to dasatinib (Hirt et al., 2022), which showed a great potential for finding drugs targeting specific type of patients. This evidence concerns the gene MDM2 and familial pancreatic carcinoma.